Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy - a podcast by Gil Porat, M.D., FACP, CPT
from 2022-01-27T20:23:37
::
::
The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).
Now let us dig a bit more into those headlines.
Further episodes of Hospital and Internal Medicine Podcast
Further podcasts by Gil Porat, M.D., FACP, CPT
Website of Gil Porat, M.D., FACP, CPT